At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
VLY-686 (Tradipitant) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis
In Brief
A Phase 2 clinical trial evaluating VLY-686 (Tradipitant) and Placebo for Gastroparesis. Completed, enrolled 152 participants across 38 sites.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroparesis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionNov 2018
Study CompletionDec 2018
TodayJul 2026
First PostedNov 22, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.6 years ago
Interventions
VLY-686 (Tradipitant)drug
oral capsule
Placeboother
placebo oral